PUMA BIOTECHNOLOGY, INC.

Nasdaq:PBYI

Pharmaceutical Preparations·LOS ANGELES, CA

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CEO

Auerbach Alan H

CFO

Nougues Maximo F

Summary Financials

Revenue

$235.6M

+3.3% YoY

FY 2025

Adj. EBITDA

$44.2M

18.7% margin

FY 2025

Net Income

$21.6M

9.2% margin

FY 2025

EPS (Diluted)

$0.45

FY 2025

Stock Price

$6.22

+2.8%

2026-03-09

52W Range

$2.58 – $7.68

P/E Ratio

13.8x

Market Cap

$316.5M

Cash

$69.2M

FY 2025

Total Debt

$21.7M

FY 2025

Net Cash

$47.5M

FY 2025

Enterprise Value

$269.0M

Debt / EBITDA

-1.1x

FY 2025

EV / EBITDA

6.1x

Employees

—

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CEO

Auerbach Alan H

CFO

Nougues Maximo F

Revenue

$235.6M

+3.3% YoY

FY 2025

Adj. EBITDA

$44.2M

18.7% margin

FY 2025

Net Income

$21.6M

9.2% margin

FY 2025

EPS (Diluted)

$0.45

FY 2025

Stock Price

$6.22

+2.8%

2026-03-09

52W Range

$2.58 – $7.68

P/E Ratio

13.8x

Market Cap

$316.5M

Cash

$69.2M

FY 2025

Total Debt

$21.7M

FY 2025

Net Cash

$47.5M

FY 2025

Enterprise Value

$269.0M

Debt / EBITDA

-1.1x

FY 2025

EV / EBITDA

6.1x

Employees

—